Q-omics provides the consensus-scored ACKR4 profile across patient tissues and cancer cell-line models. ACKR4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ACKR4 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, ACKR4 RNA expression shows 16,967 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where ACKR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACKR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACKR4 survival associations across molecular data types. ACKR4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACKR4 RNA expression–survival associations across cancer types. High ACKR4 expression shows unfavorable associations in ACC, THCA and PAAD, but favorable associations in CHOL, COAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ACKR4 RNA expression.
This table summarizes ACKR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACKR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACKR4 shows lower tumor expression in BLCA, LUAD, LUSC, COAD and UCEC and higher tumor expression in KIRP. The BLCA box plot shows higher ACKR4 RNA expression in normal versus tumor tissue (log2 FC = −1.657, t-test p < 0.001).
This table shows molecular features associated with ACKR4 in patient tissues and cancer cell lines. In patient samples, ACKR4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACKR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
